Candel Therapeutics, Inc.

CADL

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
SEC CIK: 0001841387

SEC filings (opens in a new tab)

In the last 90 days, Candel Therapeutics, Inc. insiders filed 0 open-market purchases and 2 sales; 137 institutions reported holding it in 13F filings for Q2 2026, worth $518.9M in total; no superinvestor holds it.

Q2 2022 vs. Q1 2022

How the institutions holding Candel Therapeutics, Inc. changed between Q1 2022 and Q2 2022.

All holders in Q2 2022 All holders in Q1 2022

13F holders of CADL: Q1 2022 compared with Q2 2022
Measure	Q1 2022	Q2 2022	Change
Holders	23	23	0
Shares	6.67M	6.35M	−328.2K (−4.9%)
Value	$34.0M	$20.6M	−$13.4M (−39.5%)

New holders (3)

Institutions that held Candel Therapeutics, Inc. at the end of Q2 2022 but not at the end of Q1 2022.

Institutions new to CADL in Q2 2022
Institution	Shares	Value	% of portfolio
Point72 Asset Management, L.P.	743,082	$2.41M	0.01%
Point72 Hong Kong Ltd	640	$2.00K	0.00%
Wells Fargo & Company	61	$0	0.00%

Sold out (3)

Institutions that held Candel Therapeutics, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.

Institutions that sold out of CADL in Q2 2022
Institution	Shares, Q1 2022	Value, Q1 2022
683 Capital Management, LLC	40,929	$208.0K
D. E. Shaw & Co., Inc.	10,867	$55.0K
High Net Worth Advisory Group LLC	300	$2.00K